MARKET

HTGM

HTGM

HTG Molecular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6394
-0.0156
-2.38%
After Hours: 0.6350 -0.0044 -0.69% 18:44 07/10 EDT
OPEN
0.6567
PREV CLOSE
0.6550
HIGH
0.6600
LOW
0.6300
VOLUME
2.28M
TURNOVER
--
52 WEEK HIGH
1.640
52 WEEK LOW
0.2671
MARKET CAP
42.90M
P/E (TTM)
-1.3549
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HTGM stock price target is 1.300 with a high estimate of 2.000 and a low estimate of 0.7000.

EPS

HTGM News

More
HTG Molecular Diagnostics Secures Senior Term Loan from Silicon Valley Bank
GlobeNewswire · 06/25 21:01
HTG Molecular secures $10M in debt capital
Seeking Alpha - Article · 06/25 20:09
HTG Molecular Diagnostics Secures $10M Senior Term Loan from Silicon Valley Bank
Benzinga · 06/25 20:02
Edited Transcript of HTGM earnings conference call or presentation 13-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/24 13:56
HTG EdgeSeq Technology Highlights Multiple Posters Presented By Pharma Partners AT 2020 AACR Meeting
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in multiple posters presented by
Benzinga · 06/23 20:02
HTG EdgeSeq Technology Highlighted in Multiple Posters Presented by Pharma Partners at the 2020 American Association for Cancer Research Virtual Meeting
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in multiple posters presented by global pharma company partners at the American Asso
GlobeNewswire · 06/23 20:01
HTG Introduces the HTG EdgeSeq Pan B-Cell Lymphoma Panel
GlobeNewswire · 06/18 21:01
HTG Introduces HTG EdgeSeq Pan B-Cell Lymphoma Panel
Comprehensive Panel Designed to Provide Molecular Characterization of Aggressive Lymphomas TUCSON, Ariz., June 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company
Benzinga · 06/18 20:02

Industry

Advanced Medical Equipment & Technology
-0.60%
Healthcare Equipment & Supplies
-0.31%

Hot Stocks

Symbol
Price
%Change

About HTGM

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
More

Webull offers kinds of HTG Molecular Diagnostics Inc stock information, including NASDAQ:HTGM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTGM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HTGM stock methods without spending real money on the virtual paper trading platform.